Oncology medicine spending at list prices vs Cell and gene therapy venture capital and public funding deal count

Oncology medicine spending at list prices and Cell and gene therapy venture capital and public funding deal count worldwide, compared over time.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time . Different units, drawn on separate scales and clipped to the years both series publish — earlier history stays on each indicator's own page. Read the values, not the heights.

Oncology medicine spending at list prices

Unit: billion USD · 2 observations

Line chart

Forecast: dashed line, hollow markers, shaded band

Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2021 2022 2023 2024 2025 2026 2027 2028 2029 FORECAST 252 441
Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2021 2022 2023 2024 2025 2026 2027 2028 2029 FORECAST 252 441
Oncology medicine spending at list pricesOncology medicine spending at list prices. 2 observations from 2024 to 2029, ranging from 252 billion USD to 441 billion USD, of which 1 are forecasts. Latest value 441 billion USD (2029). billion USD 0 100 200 300 400 500 2021 2022 2023 2024 2025 2026 2027 2028 2029 FORECAST 252 441
View the underlying data
Oncology medicine spending at list prices
Period Type Value
2024 Actual 252 billion USD
2029 Forecast 441 billion USD
Source: IQVIA · CC BY 4.0 · Full series

Cell and gene therapy venture capital and public funding deal count

Unit: count · 3 observations

Line chart
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 30 60 90 120 150 2021 2022 2023 2024 2025 2026 2027 2028 2029 127 96
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 50 100 150 2021 2022 2023 2024 2025 2026 2027 2028 2029 127 96
Cell and gene therapy venture capital and public funding deal countCell and gene therapy venture capital and public funding deal count. 3 observations from 2021 to 2023, ranging from 96 to 127. Latest value 96 (2023). 0 50 100 150 2021 2022 2023 2024 2025 2026 2027 2028 2029 127 96
View the underlying data
Cell and gene therapy venture capital and public funding deal count
Period Type Value
2021 Actual 127
2022 Actual 97
2023 Actual 96
Source: IQVIA · CC BY 4.0 · Full series

Provenance

Where these numbers come from

Oncology medicine spending at list prices

Total spending on cancer medicines valued at list prices.

2 observations in Global · source organisations: IQVIA

Cell and gene therapy venture capital and public funding deal count

Number of venture capital and public funding transactions for cell and gene therapies in a given year.

3 observations in Global · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related